Biotech Company Updates Cannabis Transdermal Patch Technology

Zynerba Pharmaceuticals (ZYNE) released a public offering outlining its plans to roll out their pipeline of cannabinoid-based drugs. Zynerba is exploring the first controlled-delivery system for cannabinoids. The novelty of a transdermal patch has picked up steam and investor excitement in the pharmaceutical cannabis sector. However, an FDA approval is absolutely crucial for the success of any major pharmaceutical drug.

The company's pipeline of drugs consists of a new permeation-enhanced gel (ZYN002) and transdermal patch (ZYN001.) Zynerba is the only biotech company focusing on the topical application and controlled-delivery of CBD, which they believe will be more effective for treating refractory epilepsy, osteoarthritis, and fibromyalgia. The company will also explore the treatment of a condition called Fragile X syndrome.

 

Zynerba developers say the gel is more effective for the treatment of the symptoms and progression of genetic disorders. Zynerba will initiate Phase I preclinical trials for ZYN002...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://ireadculture.com/article-5989-biotech-company-updates-cannabis-transdermal-patch-technology.html